ID-93 is under clinical development by Quratis and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect ID-93’s likelihood of approval (LoA) and phase transition for Tuberculosis took place on 24 Sep 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ID-93 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
ID-93 is under development for the prevention of tuberculosis (TB). The vaccine consists of ID93, a recombinant fusion polyprotein comprised of Mycobacterium tuberculosis antigens associated with virulence or latency (Rv2608, Rv3619, Rv3620, and Rv1813) and Glucopyranosyl Lipid A Stable Emulsion (GLASE) as an immunological adjuvant. It is formulated as freeze dried (lyophilized) powder and administered through intramuscular route.
It was also under development for leprosy.
Quick View ID-93 LOA Data
|Highest Development Stage|